Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer reissued patent

Pfizer reissued patent

18th March 2009

Pfizer has been granted the reissue a patent relating to Lipitor.

In January 2007, the company had reapplied for the protection rights over RE40667.

The purpose of this was to correct a technical defect in the ‘995 enantiomer patent atorvastatin calcium.

Pfizer explained how it was the salt form of this compound it sells as Lipitor ? oral tablets that are for the early and rate-limiting step in cholesterol biosyntheses.

The firm had received a notice of allowance accepting the application to correct the technical defect on January 6th 2009.

It has been decided that the reissued protection will have the same June 2011 expiration date as the original ‘995 patent, as well as identical force and effect.

Last week, Pfizer released the findings of a study that it had sponsored of women living with metastatic breast cancer in nine countries, including the UK.

It found many sufferers wanted there to be more public discussion about the disease and further information should be made available for patients dealing with the illness.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.